Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001213900-20-020895
Filing Date
2020-08-07
Accepted
2020-08-07 16:02:26
Documents
7

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea125182-s3_actiniumpharma.htm S-3 333610
2 ea125182ex1-2_actinium.htm EX-1.2 245429
3 OPINION OF HAYNES AND BOONE LLP ea125182ex5-1_actinium.htm EX-5.1 26933
4 CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea125182ex23-1_actinium.htm EX-23.1 2174
5 GRAPHIC image_01.jpg GRAPHIC 48843
6 GRAPHIC image_02.jpg GRAPHIC 32619
7 GRAPHIC ex5-1_01.jpg GRAPHIC 6218
  Complete submission text file 0001213900-20-020895.txt   724434
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-242322 | Film No.: 201085235
SIC: 2834 Pharmaceutical Preparations